150 related articles for article (PubMed ID: 22479293)
1. Melorheostosis and its treatment with intravenous zoledronic acid.
Hollick RJ; Black A; Reid D
BMJ Case Rep; 2010; 2010():. PubMed ID: 22479293
[TBL] [Abstract][Full Text] [Related]
2. Clinical improvement in a patient with monostotic melorheostosis after treatment with denosumab: a case report.
Byberg S; Abrahamsen B; Kassem M; Ralston S; Schwarz P
J Med Case Rep; 2018 Sep; 12(1):278. PubMed ID: 30257703
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate Therapy in the Management of Symptomatic Melorheostosis of Tibia.
Sathish M; Girinivasan C; Srinivasacholan C; Gowtham P
J Orthop Case Rep; 2021 Sep; 11(9):103-106. PubMed ID: 35415166
[TBL] [Abstract][Full Text] [Related]
4. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
Berenson JR; Vescio R; Henick K; Nishikubo C; Rettig M; Swift RA; Conde F; Von Teichert JM
Cancer; 2001 Jan; 91(1):144-54. PubMed ID: 11148571
[TBL] [Abstract][Full Text] [Related]
5. Osteoma-like melorheostosis: a rare type of skeletal dysplasia depicted on FDG PET/CT.
Abi-Ghanem AS; Asmar K; Boulos F; Muwakkit S
Skeletal Radiol; 2019 Aug; 48(8):1299-1303. PubMed ID: 30680447
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of Zoledronic acid[once-yearly bisphosphonate(intravenous infusion)].].
Tanaka S
Clin Calcium; 2016; 26(11):1605-1613. PubMed ID: 27777393
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid treatment of osteoporosis: effects in men.
Johnson DA; Williams MI; Petkov VI; Adler RA
Endocr Pract; 2010; 16(6):960-7. PubMed ID: 20497935
[TBL] [Abstract][Full Text] [Related]
8. Melorheostosis of the Foot: A Case Report of A rare entity with a Review of Multimodality Imaging Emphasizing the Importance of Conventional Radiography in Diagnosis.
Ashish G; Shashikant J; Ajay P; Subhash D
J Orthop Case Rep; 2016; 6(1):79-81. PubMed ID: 27299136
[TBL] [Abstract][Full Text] [Related]
9. Atypical form of active melorheostosis and its treatment with bisphosphonate.
Donáth J; Poór G; Kiss C; Fornet B; Genant H
Skeletal Radiol; 2002 Dec; 31(12):709-13. PubMed ID: 12483433
[TBL] [Abstract][Full Text] [Related]
10. Appearance of osteolysis with melorheostosis: redefining the disease or a new disorder? A novel case report with multimodality imaging.
Osher LS; Blazer MM; Bumpus K
J Foot Ankle Surg; 2013; 52(5):602-11. PubMed ID: 23680113
[TBL] [Abstract][Full Text] [Related]
11. Bone Features of Unaffected Skeletal Sites in Melorheostosis: A Case Report.
Indirli R; Messina C; Longhi M; Guabello G; Corbetta S
J Clin Densitom; 2020; 23(4):690-694. PubMed ID: 32057643
[TBL] [Abstract][Full Text] [Related]
12. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
Berenson JR
Semin Oncol; 2001 Apr; 28(2 Suppl 6):25-34. PubMed ID: 11346862
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
McKeage K; Plosker GL
Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
[TBL] [Abstract][Full Text] [Related]
16. Dripping Wax Bone Disease - Melorheostosis - A Rare Case Scenario.
Lokesh M; Muthumanickam ; Kumar SS; Gadde S
J Orthop Case Rep; 2020 Dec; 10(9):94-97. PubMed ID: 34169026
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid: a review of its use in patients with advanced cancer.
Perry CM; Figgitt DP
Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
[TBL] [Abstract][Full Text] [Related]
19. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
[TBL] [Abstract][Full Text] [Related]
20. Melorheostosis of the ulna.
Abdullah S; Pang GM; Mohamed-Haflah NH; Sapuan J
J Chin Med Assoc; 2011 Oct; 74(10):469-72. PubMed ID: 22036140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
